Buprenorphine
- Generic Name
- Buprenorphine
- Brand Names
- Belbuca, Brixadi, Buprenex, Buprenorphine, Butrans, Sublocade, Suboxone, Subutex, Zubsolv, Buvidal, Sixmo
- Drug Type
- Small Molecule
- Chemical Formula
- C29H41NO4
- CAS Number
- 52485-79-7
- Unique Ingredient Identifier
- 40D3SCR4GZ
- Background
Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain. It is also commonly used as an alternative to methadone for the treatment of severe opioid addiction. Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose c...
- Indication
Buprenorphine is available in different formulations, such as sublingual tablets, buccal films, transdermal films, and injections, alone or in combination with naloxone.
...
- Associated Conditions
- Opioid Dependence, Severe Pain, Moderate Opioid Dependence, Moderate Pain, Severe Opioid Dependence
- Associated Therapies
- -
A Rising EU Antitrust Enforcement Tide: 'Exclusionary Disparagement' of Pharma Rivals
The EC fined Teva €462.6 million for abusing its dominant position to delay competition to Copaxone, marking the first time a pharma company was held liable for 'exclusionary disparagement.' This decision highlights the rising tide of antitrust enforcement against disparagement practices in the pharma sector, raising questions about the boundary between legitimate competition and illegal means.
IAG beats on Q3 revenue; AstraZeneca discloses 'positive' Phase 3 clinical trial
FTSE 100 futures up 12.50 points to 8,185.0. IAG's Q3 revenue rose 7.9% to €9.33bn, with 15.4% operating profit jump to €2.01bn. AstraZeneca's Texspire phase III trial showed significant nasal polyp reduction. Oaktree Capital urges Indivior board refresh for shareholder value. Health groups call for salt and sugar taxes. AI could displace 1-3m UK private sector jobs. Bentley delays full electrification to 2035. US markets mixed post-Trump victory and Fed rate decision.
FDA Approves Protega Pharmaceuticals' Roxybond for Severe Pain Management
FDA approves Protega's Roxybond, an abuse-deterrent, immediate-release 10 mg oxycodone for pain management, using SentryBond tech to reduce misuse via intranasal and IV routes. Despite over 2000 in vitro tests suggesting reduced abuse potential, Protega warns of life-threatening respiratory depression and contraindications. Roxybond aims to address the opioid epidemic, with 3-19% of pain medication users developing addiction.
Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval
Indivior's PAS for SUBLOCADE granted Priority Review by FDA; PDUFA date set for February 7, 2025. PAS seeks label updates for alternative injection sites (thigh, buttock, back of arm) and rapid induction protocol, addressing unmet needs in OUD treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath